drugset / Trial / NCT07254754
Study to Evaluate the Efficacy of Axicabtagene Ciloleucel in Patients With Late Relapse of Diffuse Large B-Cell Lymphoma
Phase 2
Recruiting
45 enrolled
Spanish Lymphoma Cooperative Group
Evidenze CRO · collabKite, A Gilead Company · collab
NaSingle-groupOpen-labelTreatment
Summary
Single-arm, open-label, multicenter, phase II trial aiming to include approximately 45 patients over 24 months. Patients will receive axicabtagene ciloleucel infusion and will be followed up to 5 years. The total duration of the study is therefore of 7 years.
Timeline
- Start
- 2024-11-20
- Primary completion
- 2027-01-31
- Completion
- 2031-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Axicabtagene Ciloleucel | Cell therapy | 2e+06 cells/kg | Other |